^
    13h
    Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Feb 2030 | Trial primary completion date: Dec 2027 --> Feb 2030
    Trial completion date • Trial primary completion date
    |
    Gomekli (mirdametinib)
    14h
    FT819 in Subjects With B-cell Malignancies (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Fate Therapeutics | Trial primary completion date: Sep 2024 --> Jun 2025
    Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • FT819
    18h
    From chronic gastritis to gastric cancer: Mendelian randomisation and multi-omics interrogation of leukaemia inhibitory factor receptor (LIFR), hepatocyte growth factor (HGF), serine protease inhibitor E1 (SERPINE1) and interleukin-10 receptor subunit beta (IL10RB). (PubMed, Int J Biol Macromol)
    Collectively, these data define a molecular continuum from chronic gastritis to GC and highlight LIFR, IL10RB, SERPINE1 and HGF as pivotal biological macromolecules and candidate therapeutic targets. The repurposing potential of anti-inflammatory agents, particularly rofecoxib and nabumetone, suggests a feasible strategy to intercept the gastritis-carcinoma sequence.
    Journal
    |
    IL10 (Interleukin 10) • LIFR (LIF Receptor Subunit Alpha) • SERPINE1 (Serpin Family E Member 1)
    18h
    Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial. (PubMed, Lancet Haematol)
    In patients with Richter transformation, epcoritamab monotherapy showed clinically meaningful antitumour activity, although the investigator-assessed overall response rate was below the alternative hypothesis of 50%, with a safety profile consistent with previous studies. These findings support further investigation of epcoritamab as a potential treatment option for patients with Richter transformation.
    P1/2 data • Journal
    |
    TP53 (Tumor protein P53)
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epkinly (epcoritamab-bysp)
    18h
    Discovery of potent indole-2-one-based BRD4 PROTACs for the treatment of acute myeloid leukemia. (PubMed, Bioorg Chem)
    Moreover, assessments of drug-like properties indicated that compound P6 possesses favorable hepatic microsomal metabolic stability (t1/2 = 49.5 min; Cl = 0.028 mL/min/mg), and it exhibited a high safety profile in vivo. Collectively, these findings suggest that compound P6 holds promise as a potential BRD4 degrader for further exploration and development.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BRD4 (Bromodomain Containing 4)
    18h
    A medicinal chemistry perspective on disruptor of telomeric silencing 1-like: Its mechanisms and modulators in cancer treatment. (PubMed, Eur J Med Chem)
    This review comprehensively summarizes the structure and biological functions of DOT1L, focusing on the research progress of small-molecule modulators, including nucleoside/non-nucleoside inhibitors, protein-protein interaction (PPI) disruptors, dual-target inhibitors, and proteolysis-targeting chimera (PROTAC) molecules, from the perspective of drug design. In addition, this review discusses challenges and future perspectives associated with the discovery of DOT1L-targeted therapies for cancer.
    Review • Journal
    |
    DOT1L (DOT1 Like Histone Lysine Methyltransferase)
    19h
    A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, BeOne Medicines
    New P3 trial
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • sonrotoclax (BGB-11417)
    21h
    Autologous Bedside CD19 CAR T-cell Therapy for B-ALL (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, The General Hospital of Western Theater Command
    New P1 trial
    21h
    French Registry of First-line Treatment of Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P=N/A, N=400, Active, not recruiting, Groupe Francophone des Myelodysplasies | Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Jul 2026 | Trial primary completion date: Oct 2020 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    RARA (Retinoic Acid Receptor Alpha)
    |
    Chr t(15;17)
    21h
    KEYNOTE145: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • Calquence (acalabrutinib)
    24h
    Prognostic significance of caspase 8 associated protein 2 (CASP8AP2) in childhood b cell acute lymphoblastic Leukemia. (PubMed, Discov Oncol)
    Higher initial CASP8AP2 gene expression was associated with favorable impact on event-free survival in pediatric ALL patients. Post-induction levels did not show similar correlation. Future larger studies are needed to confirm the favorable association and to search for other possibly related prognostic factors to further refine risk stratification.
    Journal
    |
    CASP8 (Caspase 8) • CASP8AP2 (Caspase 8 Associated Protein 2)
    24h
    Hepatic leukemia factor directs tissue residency of proinflammatory memory CD4+ T cells. (PubMed, Science)
    HLF+ CD4+ TRM cells isolated from inflamed airway tissue in humans had a tissue residency signature and expressed inflammatory cytokines. We conclude that HLF may act as a central regulator of proinflammatory CD4+ TRM cell development and function.
    Journal
    |
    CD4 (CD4 Molecule)